Concord Biotech (NSE:CONCORDBIO, BOM:543960) completed a four-day regulatory inspection for its Limbasi manufacturing facility in India.
The Brazilian Health Regulatory Agency's ANVISA inspection confirmed the company's quality and regulatory standards and supports its international expansion plans, according to a Friday filing from the biopharmaceutical company.